FOLFIRINOX for Advanced Pancreatic Cancer Patients After Nab-Paclitaxel Plus Gemcitabine Failure-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

FOLFIRINOX for Advanced Pancreatic Cancer Patients After Nab-Paclitaxel Plus Gemcitabine Failure

Published:2020-04 Issue:4 Volume:49 Page:574-578
ISSN:1536-4828
Container-title:Pancreas
language:en
Short-container-title:Pancreas

Author:

Matsumoto Toshihiko,Kurioka Yusuke,Okazaki Ukyo,Matsuo Yu,Kimura Shogo,Miura Kou,Tsuduki Takao,Takagi Shinjiro,Takatani Masahiro,Morishita Hirofumi

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Endocrinology,Hepatology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference18 articles.

1. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial;J Clin Oncol,1997

2. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer;N Engl J Med,2011

3. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine;N Engl J Med,2013

4. A phase II study of modified FOLFIRINOX for chemotherapy-naive patients with metastatic pancreatic cancer;Cancer Chemother Pharmacol,2018

5. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer;Br J Cancer,2016

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical outcomes of second-line chemotherapy in patients with advanced pancreatic adenocarcinoma: a real-world study;Cancer Biology & Medicine;2024-07-26

2. Survival outcome of different treatment sequences in patients with locally advanced and metastatic pancreatic cancer;BMC Cancer;2024-01-12

3. Clinical Significance of Increased Skeletal Muscle Mass During Nab-Paclitaxel Plus Gemcitabine Treatment in Patients With Advanced Pancreatic Cancer;Pancreas;2023-12-28

4. Systemic therapy for metastatic pancreatic cancer;Malignant tumours;2023-10-09

5. Oxaliplatin plus irinotecan vs irinotecan as second-line treatment in pancreatic cancer patients: a randomized–controlled open-label Phase II study;Gastroenterology Report;2022-12-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3